Stock Locations

New Jersey, USA
Czech Republic, EU
Mumbai, India

* Stock subject to availability.

Documentation

Download MSDS

Download Sample COA

Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.

Atorvastatin Cyclic 1,3-Oxazine (Isopropyl) Methyl Ester Impurity

● In Stock

Catalogue No.:	VE0026709
CAS No.:	N/A
Mol. Formula:	C34H37FN2O7
Mol. Weight:	604.7 g/mol

Request a quote

Add to RFQ list

Additional information on

Parent drug

Atorvastatin

IUPAC Name

Methyl 4-[5-(4-fluorophenyl)-5-hydroxy-4-phenyl-2-(phenylcarbamoyl)-1-propan-2-yl-3,10-dioxa-6-azatricyclo[4.4.0.02,4]decan-9-yl]-3-hydroxybutanoate

Pharmacopeial Synonyms

N/A

Synonyms

N/A

Smiles

O=C(OC)CC(O)CC1CCN(C(C2=CC=C(F)C=C2)(O)C3(C4=CC=CC=C4)C5(C(NC6=CC=CC=C6)=O)O3)C5(C(C)C)O1

InChI

InChI=1S/C34H37FN2O7/c1-22(2)34-32(30(40)36-26-12-8-5-9-13-26)31(44-32,23-10-6-4-7-11-23)33(41,24-14-16-25(35)17-15-24)37(34)19-18-28(43-34)20-27(38)21-29(39)42-3/h4-17,22,27-28,38,41H,18-21H2,1-3H3,(H,36,40)

Description

Atorvastatin Cyclic 1,3-Oxazine (Isopropyl) Methyl Ester Impurity is a process-related impurity featuring a cyclized 1,3-oxazine ring with an isopropyl methyl ester substituent that can form through intramolecular cyclization or unintended esterification during synthesis or storage. Effective characterization relies on HPLC for quantitation, LC-MS for molecular weight confirmation, and NMR for definitive structural assignment, supporting impurity profiling and specification development. Mitigation strategies include reaction parameter optimization, targeted purification such as preparative chromatography, and accelerated stability studies to monitor formation pathways. Robust identification and quantitation are critical for quality control, regulatory submissions, and risk assessment in atorvastatin manufacture.